Why Small CDMOs Matter in Pharma
The role of small-sized CDMOs in securing pharma innovation pipelines.
Dr. Max Lauwiner, CEO of Valsynthese, explains how small CDMOs offer agility, proximity and senior technical attention that benefits early-stage and innovative programs.
Dr. Max Lauwiner, CEO of Valsynthese, explains how small CDMOs offer agility, proximity and senior technical attention that benefits early-stage and innovative programs.
Agility and Proximity
Small partners respond quickly, adapt to changing project needs and give sponsors direct access to senior scientists.
Specialized Chemistry
Focused expertise in complex or niche chemistry can unlock programs that larger organizations deprioritize.
Supply Chain Resilience
A diversified network of specialist suppliers reduces concentration risk in the pharmaceutical supply chain.
Download This White Paper
Biotechnology Media Insights
Continue to Biotechnology Media Insights to access this white paper.